Evaluation of combinations of bedaquiline, moxifloxacin,...

In the News

Study establishes link between gender, extramarital affairs and HIV

Dar es Salaam. A new Ifakara Health Institute study has found “a significant association between lifetime (proxy) extramarital affairs and HIV infection among women only,” with the risk being significantly …

IHI names winners of research, innovation fund

[Right-Left] Getrud, Beatrice, Theckla, and Tutu.Ifakara Health Institute (IHI) has named recipients of the 2017/18 Director’s Research and Innovation Fund. This is an internal funding mechanism aimed to support specific …

Recent Projects

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Demonstrating complete disruption of residual malaria transmission by eliminating Anopheles funestus mosquitoes from rural Tanzanian villages

In rural south-eastern Tanzania, where malaria prevalence has reduced by >60% since 2000, low-to-moderate transmission still persists despite very high coverage with long-lasting insecticidal bednets. Like in most residual transmission …

A phase 2 Open‐Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide during 8 weeks of treatment in Adult Subjects with Newly Diagnosed Drug‐Sensitive or Multi Drug‐ Resistant, Smear‐Positive Pulmonary Tuberculosis.

NC005 is a multicenter phase 2 Open‐Label Partially Randomized Trial to evaluate the efficacy, safety and tolerability of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide during 8 weeks of treatment in Adult Subjects with Newly Diagnosed Drug‐Sensitive or Multi Drug‐ Resistant, Smear‐Positive Pulmonary Tuberculosis. The primary objective of the study is to assess the mycobactericidal activity of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide regimens during 8 weeks of treatment. IHI enrolled only drug sensitive TB participants, whereby 31 participants were enrolled. Participants were randomized to receive either bedaquilline 400mg (J) (loading dose/t.i.w.), Pa824 200mg (Pa) and Pyrazinamide 1500mg (Z); or J (200mg)PaZ; or HRZE. The HRZE treatment arm is included as a control for the drug‐sensitive treatments. Enrollment and follow up complemented in February 2016 and currently participants are on a six monthly telephonic survival follow up until early 2018.

Lead Scientists:

Frederick Haraka

Francis Mhimbira

Partners

Mbeya Medical Research Centre-NIMR
TB Alliance
Swiss Tropical and Public Health Insitute

Funders

Global Alliance for TB drug development (TB Alliance)

Projects Location

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016